Clinical Trials Logo

Asthmatic clinical trials

View clinical trials related to Asthmatic.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06133985 Completed - Asthmatic Clinical Trials

Effects of Costovertebral Joint Mobilization on Respiratory Function in Asthmatic Patients

Start date: October 1, 2023
Phase: N/A
Study type: Interventional

The aim of this randomized controlled trial is to determine the effectiveness of costovertebral joint mobilization on lung function in asthmatics. By targeting the thoracic region, costovertebral mobilization can play a valuable role in enhancing respiratory function and improving the overall well-being of individuals with respiratory conditions.

NCT ID: NCT05904002 Completed - Asthmatic Clinical Trials

Effect of Incentive Spirometery on Asthmatic Pregnant Women

Start date: September 20, 2020
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the effect of the incentive spirometer on asthma during pregnancy.

NCT ID: NCT04650464 Completed - Asthmatic Clinical Trials

Cardiopulmonary Fitness in Children With Asthma Versus Healthy Children

VO2asthma
Start date: November 1, 2010
Phase:
Study type: Observational

Asthma is the most common chronic disease in children worldwide. Asthma is characterised by a chronic inflammatory disorder of the airways,episodes of wheezing, breathlessness, chest tightness and coughing. There is a large variability of asthma prevalence between countries from 11 to 15% for children in developed countries. Asthma may limit the patient's ability to be physically active and can lead to a sedentary lifestyle and affect patients' quality of life. Indeed, long-term goal of asthma management as any chronic disease is to control symptoms in order to ensure a normal quality of life to children with asthma In 1980, the World Health Organization stated that functional capacity explorations best reflect the impact of a chronic disease on the quality of life. Indeed, cardiopulmonary exercise test (CPET) has become the "gold standard" in functional evaluation of cardiorespiratory diseases in adults gradually extended to children. Physical fitness is evaluated by maximal oxygen uptake "VO2 max" during a CPET. CPET also allows to determine possible limiting factors (cardiac limitation, ventilatory limitation, muscular deconditioning) responsible for a lower VO2max. There is actually contradictory evidence regarding the aerobic fitness levels of asthmatic children and it remains unclear whether significant differences exist between asthmatic children and their non-asthmatic counterparts. Few studies suggest ventilatory exercise limitations linked to the severity of bronchial obstruction whether others put in light the impact of muscular deconditioning in the asthmatic population. In this context, the investigators aimed to compare the cardiopulmonary fitness of children with asthma with that of age-adjusted and gender-adjusted controls. The investigators also intended to identify clinical characteristics associated with VO2max in this population.

NCT ID: NCT04267666 Completed - Clinical trials for Postmenopausal Symptoms

Inspiratory Muscle Strength Training and Incentive Spirometer on Postmenopausal Asthmatic Women

training
Start date: July 1, 2019
Phase: N/A
Study type: Interventional

Objective: To compare the effectiveness of inspiratory muscle training (IMT) and incentive spirometer on ventilatory functions in post-menopausal asthmatic women. Participants and methods: A total of forty postmenopausal women suffering from asthma, their ages ranged from 50 to 60 years old, and their body mass index of the patient don't exceed 30kg/m2. They were recruited from patient chest clinic in Kasr -El- Ainy Teaching Hospital, Cairo University, Egypt.

NCT ID: NCT02967393 Completed - Asthmatic Clinical Trials

Influenza Vaccine Feasibility Study in Children With Persistent Asthma

Start date: October 10, 2016
Phase: Phase 4
Study type: Interventional

This study is designed to note whether a larger safety study using quadrivalent live attenuated influenza vaccine (LAIV4) versus quadrivalent inactivated influenza vaccine (IIV4)(FLUARIX®), would be feasible in children with persistent asthma. Half of the patients in this study will receive the FLUARIX® influenza vaccine, while the other half will receive a cell cultured quadrivalent inactivated influenza vaccine (ccIIV4)(Flucelvax®) being used as a surrogate for LAIV4.

NCT ID: NCT02383069 Completed - Children Clinical Trials

Pulmonary Rehabilitation in Asthmatic Patient

Start date: February 2015
Phase: N/A
Study type: Interventional

Asthma is one of the main chronic diseases in childhood and it is characterized by the inflammation of airways. Individuals with chronic lung disease are more susceptible to present reduction in exercise tolerance due to pulmonary limitations. The pulmonary rehabilitation may improve the physical capacity in asthmatic patients, as observed in other chronic lung diseases.

NCT ID: NCT02227394 Completed - Asthma Clinical Trials

Study to Compare the Effects of Z7200 And Symbicort® Turbohaler on Respiratory Imaging Parameters in Asthmatic Patients

Start date: August 2014
Phase: Phase 2
Study type: Interventional

Primary objective: The primary objective of this study is to evaluate the effect of the products under investigation on functional respiratory imaging parameters and evaluate the particle deposition with Computational fluid dynamics (CFD). Secondary Objectives: The secondary objectives of this study were to assess the effect of test product and reference product on: - lung function (spirometry and body plethysmography), - exercise capacity (6-Minute Walking Test [6MWT] or equivalent method to measure exercise tolerance), - dyspnea (Borg Category [C] Ratio [R] 10 [Borg CR10] scale and Visual Analogue Scale [VAS] dyspnea). Furthermore, the safety of the test product and reference product was evaluated through monitoring of AEs throughout the study.

NCT ID: NCT01738087 Completed - Asthmatic Clinical Trials

Lung Bioavailability and Total Systemic Exposure to Beclomethasone17MonoPropionate and Formoterol Across Two Strengths of NEXThaler Inhalation Powder

Start date: November 2012
Phase: Phase 2
Study type: Interventional

The study is aimed to assess the dose proportional total systemic exposure (when the administration is without the activated charcoal) to B17MP (active metabolite of BDP) and its lung bioavailability (when the administration is with the activated charcoal) after single inhalation of CHF 1535 NEXThaler DPI at two dose strengths. At the same time, the study will assess if the lung deposition and the total systemic exposure to Formoterol is affected by increasing doses of BDP.

NCT ID: NCT01022931 Completed - Healthy Clinical Trials

Epidemiology and Clinical Presentation of H1N1 Infection in Children in Geneva

Start date: October 2009
Phase: N/A
Study type: Observational

This study aims to identify clinical symptoms and outcomes, as well as response to anti-viral treatment in children living in Geneva, with influenza A/ H1N1 infection during the current pandemic.

NCT ID: NCT00836368 Completed - Asthma Clinical Trials

In Vitro Basophil Responsiveness to Allergen Challenge After Gamma-tocopherol Supplementation in Allergic Asthmatics

Gammaphil
Start date: December 2008
Phase: Phase 1
Study type: Interventional

Purpose: This is a non-masked study with a primary endpoint of in vitro basophil activation by the allergen D. farinae, comparing basophil activation before and after seven days of supplementation. Secondary endpoints will include circulating antioxidant levels (tocopherols and metabolites), in vitro basophil activation to IgG anti-IgE and to N-formyl-methionyl-leucyl-phenylalanine (f-met-leu-phe), and monocyte and basophil responsiveness to in vitro endotoxin challenge. Participants: Twenty allergic asthmatic volunteers Procedures (methods): Volunteers will be given 1200 mg of a gamma tocopherol enriched supplement, a commercially available supplement form of vitamin E. Study participants will undergo assessment of general health, lung function assessment, symptom scoring, and epicutaneous skin test to allergens at baseline and after supplementation. Blood samples will be collected at baseline and after 7 days of gamma-T treatment.